In exploratory analyses , adjusted mean Unified Parkinson 's Disease Rating Scale ( UPDRS ) PartsII + III scores ( excluding ex-placebo recipients ) remained substantially improved from DB baseline scores prior to pramipexole introduction , at -6.6 and -6.3 points amongst ex-DB-ER and ex-DB-IR recipients after 113 weeks of pramipexole ( 33 DB plus 80 OL ) in early PD , and -11.5 and -9.1 after up to 113 weeks ( up to 33 DB plus 80 OL ) in advanced PD .